Dihydrotanshinone I inhibits ovarian tumor growth by suppressing ITGB1/FAK-mediated extracellular matrix signaling.

BACKGROUND

Ovarian cancer is a major lethal malignancy of the female reproductive system. Dihydrotanshinone I (DHT) is a tanshinone compound derived from Salvia miltiorrhiza and possesses significant anti-ovarian cancer activity. However, the mechanism underlying its antitumor effect remains unclear.

PURPOSE

This study aimed to evaluate the antitumor effect of DHT on ovarian cancer and elucidate the mechanisms through proteomics analysis.

METHODS

ES2 ovarian cancer nude mice were established and 4D label-free quantitative proteomics was performed. Bioinformatics analysis, RT-PCR, and western blot were conducted for validation. Further confirmation was achieved by shRNA knockdown, CCK-8 assay, wound healing, transwell, and western blot analysis.

RESULTS

DHT significantly inhibited tumor growth in ES2 xenograft nude mice. Mechanistically, proteomics and GSEA analysis showed that DHT strikingly inhibited pathways related to extracellular matrix (ECM) receptor interaction, cell adhesion molecules, and focal adhesion. RT-PCR and western blot indicated integrin β1 (ITGB1) as a potential target of DHT. DHT downregulated ITGB1 and its downstream effector, focal adhesion kinase (FAK), both in vitro and in vivo. Bioinformatics analysis revealed that high ITGB1 expression correlated with poor prognosis in ovarian cancer patients. Knockdown of ITGB1 markedly inhibited cell viability, wound healing, and migration ability in ES2 cells, and reduced the expression of anti-apoptosis protein Bcl2, ECM proteins FAK, FN1, and cell adhesion protein Claudin1. Additionally, DHT attenuated ECM activator pyrintegrin-induced migration in ES2 cells.

CONCLUSION

These findings demonstrate that DHT inhibits ovarian tumor growth by suppressing ECM pathway via the ITGB1/FAK axis, highlighting its potential as a therapeutic candidate for ovarian cancer treatment.